1. Our Path Forward
Joe Feczko
Senior Vice President & Chief Medical Officer

2. Forward-Looking Statements
Our discussions at this meeting will include forward-looking statements.
Actual results could differ materially from those projected in the forward-
looking statements. The factors that could cause actual results to differ
are discussed in Pfizer’s 2007 Annual Report on Form 10-K and in our
reports on Form 10-Q and Form 8-K.
These reports are available on our website at www.pfizer.com in the
quot;Investors—SEC Filingsquot; section.

3. The Forces at Work in Healthcare Today
ty in
ng Socie orld
in
ances gy Agi
Adv ed W
found Technolo Develop
Pr o nd Risi
ence a
Sci ng M
in D iddle
eve
lopi Class
Info Reg
Exp rmatio ions ng
n
l
New osion &
Med
ia
m Health US
eris
m ca
Conso re Plans
n su
Co lidatin
g
Shift in Who
“ Owns” the D
ata
Transp
a
Cost an rency of Affordability
d Quali
ty

4. 5 Key Strategies
Refocus
and Optimize
the Patent-
protected
Portfolio
Instill a Find New
Culture of Opportunities
Innovation and for
Continuous Established
Improvement Products
Invest in Grow in
Complementary Emerging
Businesses Markets

5. 5 Key Strategies
Refocus
and Optimize
the Patent-
protected
Portfolio
Instill a Find New
Culture of Opportunities
Innovation and for
Continuous Established
Improvement Products
Invest in Grow in
Complementary Emerging
Businesses Markets

6. Disease Area Priorities
Invest to Win
First or High Market High
Best in Class Growth Unmet Need
Oncology
Pain
Immunology / Inflammation
Diabetes / Obesity
Alzheimer’s Disease
Schizophrenia

7. Today’s Phase 3 Portfolio
axitinib – Pancreatic Cancer PD-332334 – GAD
tremelimumab – Melanoma S,S-reboxetine – Fibromyalgia
NMEs
apixaban – VTE Prevention Zithromax/chloroquine – Malaria
CP-945598 – Obesity
New
Indications apixaban –
/
Atrial Fibrillation

8. Projected 15–20 Phase 3 Starts 2008–2009
PF-3187207 PF-885706 – GERD PF-868554 PF-734200
– Glaucoma – HCV – Diabetes
PF-299804 – Cancer
CP-751871 PF-4194471 PF-4522625
PH-797804 – RA
– Lung Cancer – HIV – Seasonal Flu
NMEs IV sulopenem/Oral
PF-4383119 CP-690550 UK-453061
sulopenem pro-drug
– OA Pain – RA – HIV
– Bacterial Infections
PD-200390
– Insomnia
apixaban – VTE PF-4383119
treatment & ACS – Chronic Pain
axitinib – RCC & tremelimumab – CRC
New Lung
S,S-reboxetine – DPN
Indications

9. Potential New Indications Expected
To Drive Value
Colorectal
es
nu
ve
Non Small Cell Lung
Re
Hepatocellular Carcinoma
Breast
Renal Cell Carcinoma & Gastrointestinal Stromal Tumor
Time

10. Projected 15–20 Submissions 2010–2012
axitinib – Pancreatic Cancer Zithromax/chloroquine PF-734200 – Diabetes
– Malaria
S,S-reboxetine PD-200390 – Insomnia
– Fibromyalgia PF-299804 – Cancer
CP-751871
CP-945598 – Obesity PF-885706 – GERD – 3rd Line NSCLC
NMEs PD-332334 – GAD PF-4522625 – Seasonal Flu PF-4383119 – OA Pain
IV sulopenem / Oral PH-797804 – RA CP-690550 – RA
sulopenem pro-drug
PF-868554 – HCV
– Bacterial Infections
PF-4194471 – HIV
UK-453061 – HIV
axitinib – 1st Line S,S-reboxetine – DPN
nd
NSCLC & 2 Line RCC CP-690550 – Psoriasis
apixaban – VTE PF-4383119
New Treatment, AF & Acute – Chronic Pain
Coronary Syndrome
Indications
/

11. Steps to Improve Execution
Focus Resources
Identify Winners Early
on Best
Opportunities
Improve Clinical Trial Design to Increase
Improve Clinical Probability of a Positive Result
Trial Execution
Improve Cycle Times

12. Optimizing the Patent-Protected Portfolio

13. Lipitor: Maintaining Leadership Under
Intense Competition
2008 Focus
Lipitor 2007 Worldwide Sales
Reinforce differentiation with
U.S.
Japan/Asia
compelling body of clinical
$7.8B
$1.5B
and outcomes evidence
(-6%)
(+7%)
Drive activities targeted at
Canada/
new and continuing patients
Latin
America/
Africa/
Maintain and leverage
Middle East
access
$1.3B
(+9%)
Communicate data from
Europe
Lipitor’s strong clinical
$3.0B
program
(-3%)
Source: IMS MAT 4Q2007

14. Global Lyrica Forward Plan:
Differentiate, Grow and Expand
2007 2008 +
Core Indications Strengthen Core and Expand
Restless
Legs
Syndrome
Epilepsy
Neuropathic
Neuropathic
Pain
Pain
GAD Post Op
Epilepsy Pain
Fibro
Fibromyalgia
GAD

15. Celebrex:
Preserve Today & Set the Stage for Growth
Strengthen
Repair the Patient- Optimize
Near-Term Understanding of
Physician Dialogue Execution
Efficacy & Safety
Completion of Large Safety Studies
Mid-Term
(CONDOR, PRECISION)

16. Chantix: For Smokers Motivated to Quit
45M Smokers 25M Smokers
in the U.S. Motivated to Quit
Control
Immature
Takers
Quitters
26%
25%
11.7M
Desire to Quit
Chantix
Target
MD/Rx-
Defiant Dependent
Smokers Quitters
20% 29%
13.0M
Openness to Medical Intervention

17. Sutent: The Bedrock of
Our Oncology Portfolio
U.S. Potential New Indications
mRCC Patient Share – 1st Line Expected to Drive Value
70%
60%
CRC
53%
50%
es
nu
40%
ve
NSCLC
Re
HCC
30%
Nexavar, 25%
BC
20%
cytokine, 11%
10%
Torisel, 7% RCC / GIST
Other, 5%
0%
J FMAMJ J ASOND
Time
2007
Source: ImpactRx

18. 5 Key Strategies
Refocus
and Optimize
the Patent-
protected
Portfolio
Instill a Find New
Culture of Opportunities
Innovation and for
Continuous Established
Improvement Products
Invest in Grow in
Complementary Emerging
Businesses Markets

19. The Opportunity
Global Pharmaceutical Sales ($ billions USD)
$898
CAGR
“Established”
$576
11% Market Is:
$523
Established Big
Products
$271 Fast growing
(Near-Post
LOE) Profitable
Innovative
4%
$375
$305
Products
(Pre-LOE)
2006 2012
* Excludes Africa/Middle East market.
Source: Datamonitor; EvaluatePharma; analyst reports.

20. The Market Is Not Homogenous,
Three Distinct Market Segments
Branded Emerging Markets
Branded Traditional Markets
IP-Driven Markets
Source: Datamonitor; EvaluatePharma; analyst reports.

21. Our Competitive Advantage =
Value Creation
Leverage
Strengths & Capabilities Our Product
Portfolio
Strong brand recognition
Track record of proven efficacy
Become a
and safety
World Leader
Strong book of business today in in Product
established products Enhancements and
Reformulation
Current portfolio about 4%
of market
Broad and deep commercial
infrastructure around the world
Pursue
Excellence in Pharmaceutical Opportunities in
“Niche” Markets
Sciences
Enhancing our value proposition
State-of-the-art manufacturing
processes and technologies Intensify Late
Stage Lifecycle
Planning

22. Our Goal – Outpace Market Growth
Increase
Emphasis on
1 Our Existing
Portfolio
Broaden the
Geographic
2 Reach of Our
Offerings
Develop
Partnerships
3 to Accelerate
Our Pace

23. 5 Key Strategies
Refocus
and Optimize
the Patent-
protected
Portfolio
Instill a Find New
Culture of Opportunities
Innovation and for
Continuous Established
Improvement Products
Invest in Grow in
Complementary Emerging
Businesses Markets

24. Right Geographies
#2 Europe
$13.3B
7.0% Share
#1 U.S. #4 Africa/ #1 Japan
#1 Asia
Middle East
$25.5B $3.7B
9.2% Share $2.6B
$0.4B 6.4% Share
5.5% Share
5.8% Share
#1 Latin
America
$1.4B
6.1% Share
The Powerful Forces of Globalization Play to Our Strength
Source: IMS MAT 4Q2007

25. Right Products
New In-Line Established
(glipizide) Extended Release Tablets
Dynastat ®
IV/IM
(parecoxib sidico injectable)

26. The Emerging Asian Markets Opportunity
Today 2012 Projection 2017 Projection
7–9%
6%
4%
$47B $79B $111B
Market Pfizer
Source: Projections based upon IMS Market Prognosis March 2007 & Internal Analysis (excludes Japan, Australia,
New Zealand)

27. Pfizer Well-Positioned and Investing
for Growth in Emerging Asian Markets
Asia Footprint People
Significant 2007 Sales Programs to develop and
Growth retain talent across markets
#1 Rank in Asia Strong cadre of very
experienced managers
Regional support footprint
in Hong Kong with cross- Three-quarters of
talent local
functional capabilities
Regional management team
Marketing and sales
together for nearly 10 years
infrastructure in all countries
Reputation as a Good Partner, Corporate Citizen and Employer
Source: IMS MAT 4Q2007 (excludes Japan, Australia, New Zealand)

28. Capturing Global Advantage –
Building Out Today’s Presence
R&D Manufacturing
$300 million investment in Manufacturing sites and experience
South Korea across Asia
R&D facility in China First trigeneration power plant in
Singapore – an environmental-
Establish incubators to aid Asian
friendly energy source
start-ups
New Asia R&D head based out of
Shanghai and reporting to M. Mackay
Business Development
Asia strategy founded on organic, internally driven growth
Business development opportunities also exist to
supplement growth and hedge against risk
New head of regional and local business development
based out of Hong Kong

29. Asia Strategy
Reinforce market leadership in the region,
grow market share from 4% to 7–9%
#1 pharma company in China, grow
market share from ~2% to ~8–11%
Goals Drive Korea to $1 billion business
Top 3 in fast-growing Asian
oncology market
Capture global advantage

30. Right
Products
Right
Business
Models
Right
Geographies

31. 5 Key Strategies
Refocus
and Optimize
the Patent-
protected
Portfolio
Instill a Find New
Culture of Opportunities
Innovation and for
Continuous Established
Improvement Products
Invest in Grow in
Complementary Emerging
Businesses Markets

32. Our Path Forward
Joe Feczko
Senior Vice President & Chief Medical Officer